Affordable Access

Access to the full text

Comprehensive Custom NGS Panel Validation for the Improvement of the Stratification of B-Acute Lymphoblastic Leukemia Patients

Authors
  • Montaño, Adrián1
  • Hernández-Sánchez, Jesús1
  • Forero-Castro, Maribel
  • Matorra-Miguel, María1
  • Lumbreras, Eva1
  • Miguel, Cristina1
  • Santos, Sandra1
  • Ramírez-Maldonado, Valentina1
  • Fuster, José Luís
  • de Las Heras, Natalia
  • García-de Coca, Alfonso
  • Sierra, Magdalena
  • Dávila, Julio2
  • de la Fuente, Ignacio
  • Olivier, Carmen
  • Olazabal, Juan
  • Martínez, Joaquín
  • Vega-García, Nerea
  • González, Teresa2
  • Hernández-Rivas, Jesús María1, 2
  • And 1 more
  • 1 (V.R.-M.)
  • 2 (T.G.)
Type
Published Article
Journal
Journal of Personalized Medicine
Publisher
MDPI
Publication Date
Sep 21, 2020
Volume
10
Issue
3
Identifiers
DOI: 10.3390/jpm10030137
PMID: 32967112
PMCID: PMC7565730
Source
PubMed Central
Keywords
License
Green

Abstract

Background: B-acute lymphoblastic leukemia (B-ALL) is a hematological neoplasm of the stem lymphoid cell of the B lineage, characterized by the presence of genetic alterations closely related to the course of the disease. The number of alterations identified in these patients grows as studies of the disease progress, but in clinical practice, the conventional techniques frequently used are only capable of detecting the most common alterations. However, techniques, such as next-generation sequencing (NGS), are being implemented to detect a wide spectrum of new alterations that also include point mutations. Methods: In this study, we designed and validated a comprehensive custom NGS panel to detect the main genetic alterations present in the disease in a single step. For this purpose, 75 B-ALL diagnosis samples from patients previously characterized by standard-of-care diagnostic techniques were sequenced. Results: The use of the custom NGS panel allowed the correct detection of the main genetic alterations present in B-ALL patients, including the presence of an aneuploid clone in 14 of the samples and some of the recurrent fusion genes in 35 of the samples. The panel was also able to successfully detect a number of secondary alterations, such as single nucleotide variants (SNVs) and copy number variations (CNVs) in 66 and 46 of the samples analyzed, respectively, allowing for further refinement of the stratification of patients. The custom NGS panel could also detect alterations with a high level of sensitivity and reproducibility when the findings obtained by NGS were compared with those obtained from other conventional techniques. Conclusions: The use of this custom NGS panel allows us to quickly and efficiently detect the main genetic alterations present in B-ALL patients in a single assay (SNVs and insertions/deletions (INDELs), recurrent fusion genes, CNVs, aneuploidies, and single nucleotide polymorphisms (SNPs) associated with pharmacogenetics). The application of this panel would thus allow us to speed up and simplify the molecular diagnosis of patients, helping patient stratification and management.

Report this publication

Statistics

Seen <100 times